系统性肥大细胞增多症和骨髓纤维化.pdf

1、Sunday,March 2,2025ModeratorNeil Love,MDFacultyThomas A Abrams,MDPrithviraj Bose,MDNatalie S Callander,MDRamaswamy Govindan,MDShilpa Gupta,MDYelena Y Janjigian,MDAhmed Omar Kaseb,MD,CMQ Samuel J Klempner,MD Andrew T Kuykendall,MD Christopher Lieu,MDStephen V Liu,MD Thomas Martin,MD Paul E Oberstein,

2、MD,MSPhilip A Philip,MD,PhD Kanwal Raghav,MD Jonathan E Rosenberg,MD Module 12:Multiple MyelomaCurrent and Emerging Therapeutic Approaches for MM Dr CallanderCAR T-Cell Therapy,Bispecific Antibodies and Antibody-Drug Conjugates Dr MartinCurrent and Emerging Therapeutic Approaches for MM Dr Callander

3、CAR T-Cell Therapy,Bispecific Antibodies and Antibody-Drug Conjugates Dr MartinModule 12:Multiple MyelomaCurrent and Emerging Therapeutic Approaches for Multiple MyelomaNatalie S Callander,MD Director,MyelomaClinicalProgramUniversity of Wisconsin CarboneCancerCenterMadison,WisconsinDisclosuresNo rel

4、evant conflicts of interest to disclose.AQUILA:StudyDesignDimopoulos.ASH2024.Abstr773.Dimopoulos.NEJM.2024;Epub.AQUILA:Baseline Disease Characteristics and PatientDispositionDimopoulos.ASH2024.Abstr773.Dimopoulos.NEJM.2024;Epub.AQUILA:PFS and PD orDeaths by IRCDimopoulos.ASH2024.Abstr773.Dimopoulos.

5、NEJM.2024;Epub.AQUILA:Disease Progressionby SubgroupsDimopoulos.ASH2024.Abstr773.Dimopoulos.NEJM.2024.AQUILA:OSDimopoulos.ASH2024.Abstr773.Dimopoulos.NEJM.2024;Epub.eastern cooperative oncology groupSmoldering MMPI:Natalie CallanderEAA173:Phase III Daratumumab to Enhance Therapeutic Effectiveness of

6、 Lenalidomide in Smoldering Myeloma(DETER-SMM)(PI:NC)Lenalidomide+DexDaratumumab+Lenalidomide+DexCR/PR/StableProg.anytimeContinue therapy For 2 yearsOff RxRANDOMIZATIONN=208/288(Activated 4/30/20 19)Phase III PERSEUS:Study Design:era of quadruplet induction,ASCT,maintenanceMRD was assessed using the